Pharmacosmos Therapeutics Inc. was established as a newly formed specialty pharmaceutical company dedicated to commercializing Monoferric for iron deficiency anemia (IDA) patients in the United States.

Waltham, Mass.-based AMAG Pharmaceuticals will secure $530 million in cash as the company divests Cord Blood Registry to GI Partners, a private equity investment firm.